Sclerotic Chronic Cutaneous Graft-versus-host-disease Following Pseudoallogeneic Chimeric Antigen Receptor T-cell Therapy
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Schneider J, Kuhlmann L, Xiao Y, Raha S, Bernhardt G, Stadler M
. Healthy-like CD4 Regulatory and CD4 Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. Int J Mol Sci. 2022; 23(18).
PMC: 9505302.
DOI: 10.3390/ijms231810914.
View
2.
Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D
. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma. Br J Haematol. 2020; 192(1):212-216.
DOI: 10.1111/bjh.17121.
View
3.
Sanber K, Savani B, Jain T
. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021; 195(5):660-668.
DOI: 10.1111/bjh.17544.
View
4.
Penas P, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A
. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002; 138(7):924-34.
DOI: 10.1001/archderm.138.7.924.
View
5.
Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M
. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplant. 2021; 57(2):215-223.
PMC: 8821014.
DOI: 10.1038/s41409-021-01515-3.
View